APO Research
Talk to an analyst

APO RESEARCH · REPORT

Preventable Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Preventable Vaccines Market Outlook and Growth Opportunities 2026

27 December 2025219 pages

Choose your research edition.

Industry ResearchPreventable Vaccines Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Preventable Vaccines Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal Preventable Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Preventable Vaccines Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Preventable Vaccines Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global Preventable Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Preventable Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Preventable Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Preventable Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Preventable Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Preventable Vaccines market include Bausch Health, Bavarian Nordic, Bharat Biotech, Crucell, Dynavax, Janssen Pharmaceuticals, LG Life Sciences, Lupin and Mitsubishi Tanabe Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Preventable Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Preventable Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Preventable Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Preventable Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Preventable Vaccines Segment by Company

Bausch Health

Bavarian Nordic

Bharat Biotech

Crucell

Dynavax

Janssen Pharmaceuticals

LG Life Sciences

Lupin

Mitsubishi Tanabe Pharma

Panacea Biotec

Protein Sciences

S K Chemicals

Serum Institute of India

Sinovac Biotech

Takeda Pharmaceutical

AstraZeneca

Baxter

GlaxoSmithKline

Pfizer

Roche

Merck

Novartis

Sanofi

Shenzhen Kangtai Biological Products

Abbott

Preventable Vaccines Segment by Type

Adult Preventable Vaccines

Pediatric Preventable Vaccines

Preventable Vaccines Segment by Application

Bacterial Diseases

Virus Diseases

Preventable Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Preventable Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Preventable Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Preventable Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Preventable Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preventable Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Preventable Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preventable Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Preventable Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Preventable Vaccines industry.

Chapter 3: Detailed analysis of Preventable Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Preventable Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Preventable Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Preventable Vaccines Industry Trends Table 2. Preventable Vaccines Industry Drivers Table 3. Preventable Vaccines Industry Opportunities and Challenges Table 4. Preventable Vaccines Industry Restraints Table 5. Global Preventable Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Preventable Vaccines Revenue Share by Company (2021-2026) Table 7. Global Preventable Vaccines Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Preventable Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Preventable Vaccines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Preventable Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Preventable Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Preventable Vaccines Company, Product Type & Application Table 13. Global Preventable Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Preventable Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Adult Preventable Vaccines Table 18. Significant Companies of Pediatric Preventable Vaccines Table 19. Global Preventable Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Preventable Vaccines Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Preventable Vaccines Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Preventable Vaccines Sales Volume Share by Type (2021-2026) Table 23. Global Preventable Vaccines Sales Volume Share by Type (2027-2032) Table 24. Global Preventable Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Preventable Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Preventable Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Preventable Vaccines Sales Value Share by Type (2021-2026) Table 28. Global Preventable Vaccines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Bacterial Diseases Table 30. Significant Companies of Virus Diseases Table 31. Global Preventable Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 32. Global Preventable Vaccines Sales Volume by Application (2021-2026) & (W Units) Table 33. Global Preventable Vaccines Sales Volume by Application (2027-2032) & (W Units) Table 34. Global Preventable Vaccines Sales Volume Share by Application (2021-2026) Table 35. Global Preventable Vaccines Sales Volume Share by Application (2027-2032) Table 36. Global Preventable Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Preventable Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Preventable Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Preventable Vaccines Sales Value Share by Application (2021-2026) Table 40. Global Preventable Vaccines Sales Value Share by Application (2027-2032) Table 41. Global Preventable Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 42. Global Preventable Vaccines Sales by Region (2021-2026) & (W Units) Table 43. Global Preventable Vaccines Sales Market Share by Region (2021-2026) Table 44. Global Preventable Vaccines Sales by Region (2027-2032) & (W Units) Table 45. Global Preventable Vaccines Sales Market Share by Region (2027-2032) Table 46. Global Preventable Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Preventable Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Preventable Vaccines Sales Value Share by Region (2021-2026) Table 49. Global Preventable Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Preventable Vaccines Sales Value Share by Region (2027-2032) Table 51. Global Preventable Vaccines Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Preventable Vaccines Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Preventable Vaccines Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Global Preventable Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Preventable Vaccines Sales by Country (2021-2026) & (W Units) Table 56. Global Preventable Vaccines Sales Market Share by Country (2021-2026) Table 57. Global Preventable Vaccines Sales by Country (2027-2032) & (W Units) Table 58. Global Preventable Vaccines Sales Market Share by Country (2027-2032) Table 59. Global Preventable Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Preventable Vaccines Sales Value Market Share by Country (2021-2026) Table 61. Global Preventable Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Preventable Vaccines Sales Value Market Share by Country (2027-2032) Table 63. Bausch Health Company Information Table 64. Bausch Health Business Overview Table 65. Bausch Health Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Bausch Health Preventable Vaccines Product Portfolio Table 67. Bausch Health Recent Development Table 68. Bavarian Nordic Company Information Table 69. Bavarian Nordic Business Overview Table 70. Bavarian Nordic Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Bavarian Nordic Preventable Vaccines Product Portfolio Table 72. Bavarian Nordic Recent Development Table 73. Bharat Biotech Company Information Table 74. Bharat Biotech Business Overview Table 75. Bharat Biotech Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Bharat Biotech Preventable Vaccines Product Portfolio Table 77. Bharat Biotech Recent Development Table 78. Crucell Company Information Table 79. Crucell Business Overview Table 80. Crucell Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Crucell Preventable Vaccines Product Portfolio Table 82. Crucell Recent Development Table 83. Dynavax Company Information Table 84. Dynavax Business Overview Table 85. Dynavax Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Dynavax Preventable Vaccines Product Portfolio Table 87. Dynavax Recent Development Table 88. Janssen Pharmaceuticals Company Information Table 89. Janssen Pharmaceuticals Business Overview Table 90. Janssen Pharmaceuticals Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Janssen Pharmaceuticals Preventable Vaccines Product Portfolio Table 92. Janssen Pharmaceuticals Recent Development Table 93. LG Life Sciences Company Information Table 94. LG Life Sciences Business Overview Table 95. LG Life Sciences Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. LG Life Sciences Preventable Vaccines Product Portfolio Table 97. LG Life Sciences Recent Development Table 98. Lupin Company Information Table 99. Lupin Business Overview Table 100. Lupin Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Lupin Preventable Vaccines Product Portfolio Table 102. Lupin Recent Development Table 103. Mitsubishi Tanabe Pharma Company Information Table 104. Mitsubishi Tanabe Pharma Business Overview Table 105. Mitsubishi Tanabe Pharma Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Mitsubishi Tanabe Pharma Preventable Vaccines Product Portfolio Table 107. Mitsubishi Tanabe Pharma Recent Development Table 108. Panacea Biotec Company Information Table 109. Panacea Biotec Business Overview Table 110. Panacea Biotec Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Panacea Biotec Preventable Vaccines Product Portfolio Table 112. Panacea Biotec Recent Development Table 113. Protein Sciences Company Information Table 114. Protein Sciences Business Overview Table 115. Protein Sciences Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Protein Sciences Preventable Vaccines Product Portfolio Table 117. Protein Sciences Recent Development Table 118. S K Chemicals Company Information Table 119. S K Chemicals Business Overview Table 120. S K Chemicals Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. S K Chemicals Preventable Vaccines Product Portfolio Table 122. S K Chemicals Recent Development Table 123. Serum Institute of India Company Information Table 124. Serum Institute of India Business Overview Table 125. Serum Institute of India Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Serum Institute of India Preventable Vaccines Product Portfolio Table 127. Serum Institute of India Recent Development Table 128. Sinovac Biotech Company Information Table 129. Sinovac Biotech Business Overview Table 130. Sinovac Biotech Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Sinovac Biotech Preventable Vaccines Product Portfolio Table 132. Sinovac Biotech Recent Development Table 133. Takeda Pharmaceutical Company Information Table 134. Takeda Pharmaceutical Business Overview Table 135. Takeda Pharmaceutical Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Takeda Pharmaceutical Preventable Vaccines Product Portfolio Table 137. Takeda Pharmaceutical Recent Development Table 138. AstraZeneca Company Information Table 139. AstraZeneca Business Overview Table 140. AstraZeneca Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. AstraZeneca Preventable Vaccines Product Portfolio Table 142. AstraZeneca Recent Development Table 143. Baxter Company Information Table 144. Baxter Business Overview Table 145. Baxter Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Baxter Preventable Vaccines Product Portfolio Table 147. Baxter Recent Development Table 148. GlaxoSmithKline Company Information Table 149. GlaxoSmithKline Business Overview Table 150. GlaxoSmithKline Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. GlaxoSmithKline Preventable Vaccines Product Portfolio Table 152. GlaxoSmithKline Recent Development Table 153. Pfizer Company Information Table 154. Pfizer Business Overview Table 155. Pfizer Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Pfizer Preventable Vaccines Product Portfolio Table 157. Pfizer Recent Development Table 158. Roche Company Information Table 159. Roche Business Overview Table 160. Roche Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Roche Preventable Vaccines Product Portfolio Table 162. Roche Recent Development Table 163. Merck Company Information Table 164. Merck Business Overview Table 165. Merck Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Merck Preventable Vaccines Product Portfolio Table 167. Merck Recent Development Table 168. Novartis Company Information Table 169. Novartis Business Overview Table 170. Novartis Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 171. Novartis Preventable Vaccines Product Portfolio Table 172. Novartis Recent Development Table 173. Sanofi Company Information Table 174. Sanofi Business Overview Table 175. Sanofi Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 176. Sanofi Preventable Vaccines Product Portfolio Table 177. Sanofi Recent Development Table 178. Shenzhen Kangtai Biological Products Company Information Table 179. Shenzhen Kangtai Biological Products Business Overview Table 180. Shenzhen Kangtai Biological Products Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 181. Shenzhen Kangtai Biological Products Preventable Vaccines Product Portfolio Table 182. Shenzhen Kangtai Biological Products Recent Development Table 183. Abbott Company Information Table 184. Abbott Business Overview Table 185. Abbott Preventable Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 186. Abbott Preventable Vaccines Product Portfolio Table 187. Abbott Recent Development Table 188. Key Raw Materials Table 189. Raw Materials Key Suppliers Table 190. Preventable Vaccines Distributors List Table 191. Preventable Vaccines Customers List Table 192. Research Programs/Design for This Report Table 193. Authors List of This Report Table 194. Secondary Sources Table 195. Primary Sources List of Figures Figure 1. Preventable Vaccines Product Image Figure 2. Global Preventable Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Preventable Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Preventable Vaccines Sales (2021-2032) & (W Units) Figure 5. Global Preventable Vaccines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Preventable Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Adult Preventable Vaccines Image Figure 10. Pediatric Preventable Vaccines Image Figure 11. Global Preventable Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Preventable Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Preventable Vaccines Sales Volume Share by Type (2021-2032) Figure 14. Global Preventable Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Preventable Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Preventable Vaccines Sales Value Share by Type (2021-2032) Figure 17. Bacterial Diseases Image Figure 18. Virus Diseases Image Figure 19. Global Preventable Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Preventable Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Preventable Vaccines Sales Volume Share by Application (2021-2032) Figure 22. Global Preventable Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Preventable Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Preventable Vaccines Sales Value Share by Application (2021-2032) Figure 25. Global Preventable Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 26. Global Preventable Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Preventable Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Preventable Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Preventable Vaccines Sales Value (2021-2032) & (US$ Million) Figure 30. North America Preventable Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Preventable Vaccines Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Preventable Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Preventable Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Preventable Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Preventable Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. South America Preventable Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Preventable Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Preventable Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Preventable Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Preventable Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Preventable Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Preventable Vaccines Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Preventable Vaccines Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Adult Preventable Vaccines
  • Pediatric Preventable Vaccines
Applications
  • Bacterial Diseases
  • Virus Diseases
Companies covered
  • Bausch Health
  • Bavarian Nordic
  • Bharat Biotech
  • Crucell
  • Dynavax
  • Janssen Pharmaceuticals
  • LG Life Sciences
  • Lupin
  • Mitsubishi Tanabe Pharma
  • Panacea Biotec
  • Protein Sciences
  • S K Chemicals
  • Serum Institute of India
  • Sinovac Biotech
  • Takeda Pharmaceutical
  • AstraZeneca
  • Baxter
  • GlaxoSmithKline
  • Pfizer
  • Roche
  • Merck
  • Novartis
  • Sanofi
  • Shenzhen Kangtai Biological Products
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Preventable Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Preventable Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Preventable Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Preventable Vaccines Market Dynamics
  1. 2.1 Preventable Vaccines Industry Trends
  2. 2.2 Preventable Vaccines Industry Drivers
  3. 2.3 Preventable Vaccines Industry Opportunities and Challenges
  4. 2.4 Preventable Vaccines Industry Restraints
3 Preventable Vaccines Market by Company
  1. 3.1 Global Preventable Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Preventable Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Preventable Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Preventable Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Preventable Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Preventable Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Preventable Vaccines Company Product Type and Application
  8. 3.8 Global Preventable Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Preventable Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Preventable Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Preventable Vaccines Market by Type
  1. 4.1 Preventable Vaccines Type Introduction
  2. 4.1.1 Adult Preventable Vaccines
  3. 4.1.2 Pediatric Preventable Vaccines
  4. 4.2 Global Preventable Vaccines Sales Volume by Type
  5. 4.2.1 Global Preventable Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Preventable Vaccines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Preventable Vaccines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Preventable Vaccines Sales Value by Type
  9. 4.3.1 Global Preventable Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Preventable Vaccines Sales Value by Type (2021-2032)
  11. 4.3.3 Global Preventable Vaccines Sales Value Share by Type (2021-2032)
5 Preventable Vaccines Market by Application
  1. 5.1 Preventable Vaccines Application Introduction
  2. 5.1.1 Bacterial Diseases
  3. 5.1.2 Virus Diseases
  4. 5.2 Global Preventable Vaccines Sales Volume by Application
  5. 5.2.1 Global Preventable Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Preventable Vaccines Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Preventable Vaccines Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Preventable Vaccines Sales Value by Application
  9. 5.3.1 Global Preventable Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Preventable Vaccines Sales Value by Application (2021-2032)
  11. 5.3.3 Global Preventable Vaccines Sales Value Share by Application (2021-2032)
6 Preventable Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Preventable Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Preventable Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Preventable Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Preventable Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Preventable Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Preventable Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Preventable Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Preventable Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Preventable Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Preventable Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Preventable Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Preventable Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Preventable Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Preventable Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Preventable Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Preventable Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Preventable Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Preventable Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Preventable Vaccines Sales Value Share by Country, 2025 VS 2032
7 Preventable Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Preventable Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Preventable Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Preventable Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Preventable Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Preventable Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Preventable Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Preventable Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Preventable Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Preventable Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Preventable Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Preventable Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Preventable Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Preventable Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Preventable Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Preventable Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Preventable Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Preventable Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Preventable Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Preventable Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Preventable Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Preventable Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Preventable Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Preventable Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Preventable Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Preventable Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Preventable Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Preventable Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Preventable Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Preventable Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Preventable Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Preventable Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Preventable Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Preventable Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Preventable Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Preventable Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Preventable Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Preventable Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Preventable Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bausch Health
  2. 8.1.1 Bausch Health Company Information
  3. 8.1.2 Bausch Health Business Overview
  4. 8.1.3 Bausch Health Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bausch Health Preventable Vaccines Product Portfolio
  6. 8.1.5 Bausch Health Recent Developments
  7. 8.2 Bavarian Nordic
  8. 8.2.1 Bavarian Nordic Company Information
  9. 8.2.2 Bavarian Nordic Business Overview
  10. 8.2.3 Bavarian Nordic Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bavarian Nordic Preventable Vaccines Product Portfolio
  12. 8.2.5 Bavarian Nordic Recent Developments
  13. 8.3 Bharat Biotech
  14. 8.3.1 Bharat Biotech Company Information
  15. 8.3.2 Bharat Biotech Business Overview
  16. 8.3.3 Bharat Biotech Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bharat Biotech Preventable Vaccines Product Portfolio
  18. 8.3.5 Bharat Biotech Recent Developments
  19. 8.4 Crucell
  20. 8.4.1 Crucell Company Information
  21. 8.4.2 Crucell Business Overview
  22. 8.4.3 Crucell Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Crucell Preventable Vaccines Product Portfolio
  24. 8.4.5 Crucell Recent Developments
  25. 8.5 Dynavax
  26. 8.5.1 Dynavax Company Information
  27. 8.5.2 Dynavax Business Overview
  28. 8.5.3 Dynavax Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Dynavax Preventable Vaccines Product Portfolio
  30. 8.5.5 Dynavax Recent Developments
  31. 8.6 Janssen Pharmaceuticals
  32. 8.6.1 Janssen Pharmaceuticals Company Information
  33. 8.6.2 Janssen Pharmaceuticals Business Overview
  34. 8.6.3 Janssen Pharmaceuticals Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Janssen Pharmaceuticals Preventable Vaccines Product Portfolio
  36. 8.6.5 Janssen Pharmaceuticals Recent Developments
  37. 8.7 LG Life Sciences
  38. 8.7.1 LG Life Sciences Company Information
  39. 8.7.2 LG Life Sciences Business Overview
  40. 8.7.3 LG Life Sciences Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 LG Life Sciences Preventable Vaccines Product Portfolio
  42. 8.7.5 LG Life Sciences Recent Developments
  43. 8.8 Lupin
  44. 8.8.1 Lupin Company Information
  45. 8.8.2 Lupin Business Overview
  46. 8.8.3 Lupin Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Lupin Preventable Vaccines Product Portfolio
  48. 8.8.5 Lupin Recent Developments
  49. 8.9 Mitsubishi Tanabe Pharma
  50. 8.9.1 Mitsubishi Tanabe Pharma Company Information
  51. 8.9.2 Mitsubishi Tanabe Pharma Business Overview
  52. 8.9.3 Mitsubishi Tanabe Pharma Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Mitsubishi Tanabe Pharma Preventable Vaccines Product Portfolio
  54. 8.9.5 Mitsubishi Tanabe Pharma Recent Developments
  55. 8.10 Panacea Biotec
  56. 8.10.1 Panacea Biotec Company Information
  57. 8.10.2 Panacea Biotec Business Overview
  58. 8.10.3 Panacea Biotec Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Panacea Biotec Preventable Vaccines Product Portfolio
  60. 8.10.5 Panacea Biotec Recent Developments
  61. 8.11 Protein Sciences
  62. 8.11.1 Protein Sciences Company Information
  63. 8.11.2 Protein Sciences Business Overview
  64. 8.11.3 Protein Sciences Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Protein Sciences Preventable Vaccines Product Portfolio
  66. 8.11.5 Protein Sciences Recent Developments
  67. 8.12 S K Chemicals
  68. 8.12.1 S K Chemicals Company Information
  69. 8.12.2 S K Chemicals Business Overview
  70. 8.12.3 S K Chemicals Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 S K Chemicals Preventable Vaccines Product Portfolio
  72. 8.12.5 S K Chemicals Recent Developments
  73. 8.13 Serum Institute of India
  74. 8.13.1 Serum Institute of India Company Information
  75. 8.13.2 Serum Institute of India Business Overview
  76. 8.13.3 Serum Institute of India Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Serum Institute of India Preventable Vaccines Product Portfolio
  78. 8.13.5 Serum Institute of India Recent Developments
  79. 8.14 Sinovac Biotech
  80. 8.14.1 Sinovac Biotech Company Information
  81. 8.14.2 Sinovac Biotech Business Overview
  82. 8.14.3 Sinovac Biotech Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Sinovac Biotech Preventable Vaccines Product Portfolio
  84. 8.14.5 Sinovac Biotech Recent Developments
  85. 8.15 Takeda Pharmaceutical
  86. 8.15.1 Takeda Pharmaceutical Company Information
  87. 8.15.2 Takeda Pharmaceutical Business Overview
  88. 8.15.3 Takeda Pharmaceutical Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Takeda Pharmaceutical Preventable Vaccines Product Portfolio
  90. 8.15.5 Takeda Pharmaceutical Recent Developments
  91. 8.16 AstraZeneca
  92. 8.16.1 AstraZeneca Company Information
  93. 8.16.2 AstraZeneca Business Overview
  94. 8.16.3 AstraZeneca Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 AstraZeneca Preventable Vaccines Product Portfolio
  96. 8.16.5 AstraZeneca Recent Developments
  97. 8.17 Baxter
  98. 8.17.1 Baxter Company Information
  99. 8.17.2 Baxter Business Overview
  100. 8.17.3 Baxter Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Baxter Preventable Vaccines Product Portfolio
  102. 8.17.5 Baxter Recent Developments
  103. 8.18 GlaxoSmithKline
  104. 8.18.1 GlaxoSmithKline Company Information
  105. 8.18.2 GlaxoSmithKline Business Overview
  106. 8.18.3 GlaxoSmithKline Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 GlaxoSmithKline Preventable Vaccines Product Portfolio
  108. 8.18.5 GlaxoSmithKline Recent Developments
  109. 8.19 Pfizer
  110. 8.19.1 Pfizer Company Information
  111. 8.19.2 Pfizer Business Overview
  112. 8.19.3 Pfizer Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Pfizer Preventable Vaccines Product Portfolio
  114. 8.19.5 Pfizer Recent Developments
  115. 8.20 Roche
  116. 8.20.1 Roche Company Information
  117. 8.20.2 Roche Business Overview
  118. 8.20.3 Roche Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Roche Preventable Vaccines Product Portfolio
  120. 8.20.5 Roche Recent Developments
  121. 8.21 Merck
  122. 8.21.1 Merck Company Information
  123. 8.21.2 Merck Business Overview
  124. 8.21.3 Merck Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Merck Preventable Vaccines Product Portfolio
  126. 8.21.5 Merck Recent Developments
  127. 8.22 Novartis
  128. 8.22.1 Novartis Company Information
  129. 8.22.2 Novartis Business Overview
  130. 8.22.3 Novartis Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Novartis Preventable Vaccines Product Portfolio
  132. 8.22.5 Novartis Recent Developments
  133. 8.23 Sanofi
  134. 8.23.1 Sanofi Company Information
  135. 8.23.2 Sanofi Business Overview
  136. 8.23.3 Sanofi Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Sanofi Preventable Vaccines Product Portfolio
  138. 8.23.5 Sanofi Recent Developments
  139. 8.24 Shenzhen Kangtai Biological Products
  140. 8.24.1 Shenzhen Kangtai Biological Products Company Information
  141. 8.24.2 Shenzhen Kangtai Biological Products Business Overview
  142. 8.24.3 Shenzhen Kangtai Biological Products Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Shenzhen Kangtai Biological Products Preventable Vaccines Product Portfolio
  144. 8.24.5 Shenzhen Kangtai Biological Products Recent Developments
  145. 8.25 Abbott
  146. 8.25.1 Abbott Company Information
  147. 8.25.2 Abbott Business Overview
  148. 8.25.3 Abbott Preventable Vaccines Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Abbott Preventable Vaccines Product Portfolio
  150. 8.25.5 Abbott Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Preventable Vaccines Value Chain Analysis
  2. 9.1.1 Preventable Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Preventable Vaccines Sales Mode & Process
  6. 9.2 Preventable Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Preventable Vaccines Distributors
  9. 9.2.3 Preventable Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst